Allergy Therapeutics - Asset Resilience Ratio

Latest as of June 2024: 0.31%

Allergy Therapeutics (AGY) has an Asset Resilience Ratio of 0.31% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check AGY strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

GBX200.00K

≈ $24.33 USD Cash + Short-term Investments

Total Assets

GBX64.83 Million

≈ $7.89K USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2007–2024)

This chart shows how Allergy Therapeutics's Asset Resilience Ratio has changed over time. See AGY net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Allergy Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Allergy Therapeutics market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	GBX0.00	0%
Short-term Investments	GBX200.00K	0.31%
Total Liquid Assets	GBX200.00K	0.31%

Asset Resilience Insights

Limited Liquidity: Allergy Therapeutics maintains only 0.31% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Allergy Therapeutics Industry Peers by Asset Resilience Ratio

Compare Allergy Therapeutics's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tonghua Dongbao Pharmaceutical Co Ltd SHG:600867	Drug Manufacturers - Specialty & Generic	0.76%
Eris Lifesciences Limited NSE:ERIS	Drug Manufacturers - Specialty & Generic	0.58%
Zhejiang Hisun Pharmaceutical Co Ltd SHG:600267	Drug Manufacturers - Specialty & Generic	0.01%
Lotus Pharmaceutical Co Ltd TW:1795	Drug Manufacturers - Specialty & Generic	0.49%
Tasly Pharmaceutical Group Co Ltd SHG:600535	Drug Manufacturers - Specialty & Generic	11.69%
Changzhou Qianhong Biopharma Co Ltd SHE:002550	Drug Manufacturers - Specialty & Generic	18.70%
Renhe Pharmacy Co Ltd SHE:000650	Drug Manufacturers - Specialty & Generic	37.54%
Sun Pharma Advanced Research Company Limited NSE:SPARC	Drug Manufacturers - Specialty & Generic	0.64%

Annual Asset Resilience Ratio for Allergy Therapeutics (2007–2024)

The table below shows the annual Asset Resilience Ratio data for Allergy Therapeutics.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-06-30	0.31%	GBX200.00K ≈ $24.33	GBX64.83 Million ≈ $7.89K	-0.40pp
2017-06-30	0.71%	GBX404.00K ≈ $49.16	GBX57.18 Million ≈ $6.96K	+18.93pp
2016-06-30	-18.23%	GBX-10.33 Million ≈ $-1.26K	GBX56.68 Million ≈ $6.90K	-19.77pp
2015-06-30	1.54%	GBX783.00K ≈ $95.27	GBX50.70 Million ≈ $6.17K	+0.33pp
2014-06-30	1.21%	GBX345.00K ≈ $41.98	GBX28.40 Million ≈ $3.46K	+1.21pp
2013-06-30	0.01%	GBX2.00K ≈ $0.24	GBX28.96 Million ≈ $3.52K	-1.73pp
2012-06-30	1.74%	GBX483.00K ≈ $58.77	GBX27.75 Million ≈ $3.38K	+1.73pp
2008-06-30	0.01%	GBX3.00K ≈ $0.37	GBX23.18 Million ≈ $2.82K	-0.25pp
2007-06-30	0.26%	GBX63.00K ≈ $7.67	GBX23.99 Million ≈ $2.92K	--

pp = percentage points

About Allergy Therapeutics

LSE:AGY UK Drug Manufacturers - Specialty & Generic

Market Cap

$5.23 Million

GBX42.99 Billion GBX

Market Cap Rank

#28458 Global

#464 in UK

Share Price

GBX7.00

Change (1 day)

-6.42%

52-Week Range

GBX7.00 - GBX12.10

All Time High

GBX38.50